Previous 10 | Next 10 |
Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16, 2020 at 8:30 a.m. EST CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Aerpio Phar...
CINCINNATI, March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will release its financial results for the fourth quarter and full ...
Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio&...
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation ...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...
Aerpio Pharms (NASDAQ: ARPO ): Q3 GAAP EPS of -$0.11 in-line. More news on: Aerpio Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2019, and provided a business update. ...
Aimed at boosting shareholder value, Aerpio Pharmaceuticals (NASDAQ: ARPO ) will explore and review a range of strategic alternatives that could include an acquisition, company or asset sale, merger, business combination, in-license, out-license or other strategic transaction. More ...
Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alte...
News, Short Squeeze, Breakout and More Instantly...
Aerpio Pharmaceuticals Inc. Company Name:
ARPO Stock Symbol:
NASDAQ Market:
Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021 under ticker symbol “AADI” Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and in...
3 Penny Stocks That Investors Are Eyeing Right Now With 2021 moving faster than ever, investors continue to look for the best penny stocks to buy. Although it can be challenging given the current market conditions, there are plenty of ways to find value with penny stocks . The m...